$SER Cashflow Statement | Understand Stock

$SER

$1.67 -$0.04 (2.34%) Close

$SER Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
OPERATING ACTIVITIES:
Net loss attributable to AgeX
Net loss attributable to AgeX from continuing operations
Net loss attributable to noncontrolling interest
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on deconsolidation of LifeMap Sciences (Note 3)
Gain on extinguishment of debt (Paycheck Protection Program loan)
Depreciation and amortization
Loss on disposal of property and equipment
Non-cash lease expense
Non-cash interest expense
Amortization of debt issuance costs and debt discounts
Gain on disposition of fixed assets
Write off of prepaid shelf registration statement related expenses
Fair value inception adjustment on convertible promissory note
Stock-based compensation
Common stock issued to consultant for services rendered
Restricted stock units released to consultant for services rendered
Change in fair value of convertible promissory notes
Change in fair value of warrants liabilities
Amortization of intangible assets
Gain on warrants expiration
Loss on sale of subsidiary
Changes in operating assets and liabilities:
Accounts and grants receivable
Grant receivable
Prepaid expenses and other assets
Interest on convertible note receivable
Accounts payable and accrued liabilities
Related party payables
Insurance premium liability
Accounts payable
Accrued expenses
Other current liabilities
Net cash used in operating activities from continuing operations
Net cash used in operating activities from discontinued operations (Note 3)
Operating lease liabilities

Net cash used in operating activities

INVESTING ACTIVITIES:
Proceeds from the sale of LifeMap Sciences (Note 3)
Partial collection on loan due from LifeMap Sciences
Net cash provided by investing activities from continuing operations
Deconsolidation of cash and cash equivalents from discontinued operations (Note 3)
Cash advanced on convertible note receivable
Purchase of equipment
Net cash used in investing activities

FINANCING ACTIVITIES:
Draw down on loan facility from Juvenescence
Proceeds from the issuance of common stock and warrants to Juvenescence
Drawdown on loan facilities from Juvenescence
Cash and restricted cash acquired in connection with the Merger
Proceeds from the exercise of stock options
Proceeds from the exercise of Post-Merger Warrants by Juvenescence
Proceeds from issuance of common stock
Juvenescence
At The Market Offering Program
Total proceeds from issuance of common stock

Net cash provided by financing activities from continuing operations
Partial payment on loan due to AgeX from discontinued operations (Note 3)
Principal repayment on loan facilities to Juvenescence
Principal repayments on finance lease liabilities
Proceeds from issuance of Series A Convertible Preferred Stock, net
Proceeds from 2025 Convertible Note, net
Net cash provided by financing activities

Effect of foreign currency on cash and cash equivalents
NET DECREASE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS:
At beginning of the year
At end of the year
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the year for interest
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:
Issuance of common stock upon vesting of restricted stock units
Issuance of preferred stock in exchange for debt
Property and equipment purchases payable as of December 31
Issuance of common stock upon conversion of redeemable convertible preferred stock
Issuance of warrants to Juvenescence (Note 5)
Issuance of warrants for debt issuance under the 2020 Loan Agreement
Issuance of warrants for debt issuance under the Secured Note (Note 6)
Fair value of liability classified warrants at debt inception date (Note 6)
Debt refinanced with new debt (Note 5)
Issuance of warrants upon exercise of Post-Merger warrants
Merger and issuance of common stock upon consummation of Merger on March 26, 2024
Deemed dividend from issuance of warrants
Derecognition of Post Merger and Incentive Warrants liability upon exchange transaction
Issuance of common stock warrants upon exchange transaction
Issuance of common stock warrants upon exercise of Post-Merger warrants
Extinguishment of debt upon sale of subsidiary
Right of use asset acquired in exchange for operating lease liabilities
Conversion of convertible promissory notes and warrants issued
Transfer of right‑of‑use assets to property and equipment upon title transfer
Issuance of common stock warrants in connection with 2025 Convertible Note
Recognition of debt discount on 2025 Convertible Note
Reclassification of warrant liability to equity

Comments